Registry of Pediatric Patients Diagnosed With Crohn's Disease in Belgium

A registry of pediatric patients (under 18 yrs of age) diagnosed with Crohn's disease was created in Belgium. Over a 2 year period 257 patients are included. These patients will be follow up prospectively during 5 years. Demographic data, family history, disease presentation and disease course including medication are registered in CRF's.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Description of Disease Course, Disease Fenotype, Medication, Safety, Analysis for Possible Associations Crohn Disease Digestive System Diseases Disease Attributes Disease Progression Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

1 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bespghan

Leuven, Brabant, 3000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1-18 yrs old belgian Crohn s disease informed consent

Exclusion criteria

no informed consent

Treatment and study plan

Primary outcomes

disease course

Time frame: 5 years

describe patient characteristics, disease fenotype and course

Sponsors and collaborators

Lead sponsor

Gigi Veereman

Other

Registry information

Official study title

Belgian Registry of Pediatric Crohn's Disease

Acronym: Belcro

Important dates

Study start: 2008
Primary completion: 2015
Study completion: 2015
First posted: Nov 16, 2010
Registry last updated: Jan 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed